<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01777503</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT Number: 2012-002882-37</org_study_id>
    <nct_id>NCT01777503</nct_id>
  </id_info>
  <brief_title>The Elderly ACS II Trial</brief_title>
  <official_title>Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcispedale Santa Maria Nuova-IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ANMCO Italian Association of Hospital Cardiologist</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Italian Society of Invasive Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Arcispedale Santa Maria Nuova-IRCCS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare reduced-dose prasugrel and standard dose
      clopidogrel in patients older than 74 years with ACS, including non-ST-elevation (NSTEACS)
      and ST-elevation (STEMI) patients, undergoing early PCI. The primary endpoint of the trial
      will be the one-year composite of (all-cause)death, myocardial infarction, stroke and
      re-hospitalization due to cardiovascular reasons or bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite of all-cause mortality, myocardial infarction (MI), disabling stroke and re-hospitalization for cardiovascular causes or bleeding within one year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The composite of burden of recurrent cardiovascular (CV) events, CV mortality, all-cause mortality and MI, major bleeding, any stroke, total number of days spent in hospital.</measure>
    <time_frame>1 year</time_frame>
    <description>definition of major bleeding:
- Bleeding Academic Research Consortium (BARC) type 2 or 3 bleeding within 1 year (for bleedings occurring during index or subsequent hospitalizations)
Â· BARC type IV bleeding within 1 year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>prasugrel 5 mg o.d.</description>
    <arm_group_label>prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75 mg o.d.</description>
    <arm_group_label>clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients &gt;74 years of age hospitalized for an ACS, with or without STE, with an onset of
        symptoms during the previous 72 hours, and candidates to an early PCI.

          -  STEMI patients may be randomized upon first diagnosis, provided they do not meet any
             exclusion criteria. STEMI patients should not exceed 50 percent of the global
             population of the study

          -  Eligible NSTEACS patients may be randomized after coronary angiography. To be
             eligible, NSTEACS patients must have at least one of the following characteristics:

               -  elevated troponin levels;

               -  diabetes mellitus;

               -  prior MI;

               -  at least one new ischemic episode while on standard treatment during the index
                  hospitalization;

               -  ACS due to stent thrombosis.

        Exclusion Criteria:

          -  History of stroke or transient ischemic attack (TIA)

          -  Gastrointestinal or genitourinary bleeding of clinical significance within 6 weeks
             prior to randomization.

          -  Hemoglobin level on admission &lt;10 g/dl, unless this is considered to be secondary to
             renal dysfunction or known myelodysplasia.

          -  Secondary causes of acute myocardial ischemia.

          -  Known current platelet count &lt; 90,000 cells/mL.

          -  Ongoing oral anticoagulant treatment or an INR known to be &gt;1.5 at the time of
             screening.

          -  Concomitant severe obstructive lung disease, malignancy or neurologic deficit limiting
             follow-up or adherence to the study protocol.

          -  Participation in any phase of another clinical research study involving the evaluation
             of another investigational drug or device within 30 days prior to randomization

          -  Inability to give at least verbal informed consent to the study.

          -  Contraindications to the use of clopidogrel or prasugrel as per package leaflet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefano Savonitto, MD</last_name>
    <phone>+39-0341-489490</phone>
    <email>s.savonitto@ospedale.lecco.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Ospedale Civile di Legnano&quot;</name>
      <address>
        <city>Legnano</city>
        <state>MI</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano De Servi, MD</last_name>
      <email>stefano.deservi@ao-legnano.it</email>
    </contact>
    <investigator>
      <last_name>Stefano De Servi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova- IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Savonitto, MD</last_name>
      <phone>+39-0341-489490</phone>
      <email>s.savonitto@ospedale.lecco.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Savonitto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1016/j.ahj.2016.08.010</url>
    <description>Design and rationale of the randomized Elderly-ACS 2 study</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2013</study_first_submitted>
  <study_first_submitted_qc>January 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>A. Manzoni Hospital</investigator_affiliation>
    <investigator_full_name>StefanoSavonitto</investigator_full_name>
    <investigator_title>dept of division of Cardiology - Manzoni Hospital</investigator_title>
  </responsible_party>
  <keyword>acute coronary syndrome</keyword>
  <keyword>elderly</keyword>
  <keyword>percutaneous revascularization</keyword>
  <keyword>antiaggregant drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

